Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway

Biochemical and Biophysical Research Communications

Volumn 422, Issue 3, 2012, Pages 398-404

  Huai, Lei ^a   Wang, Cuicui ^a   Zhang, Cuiping ^a   Li, Qihui ^a   Chen, Yirui ^a   Jia, Yujiao ^a   Li, Yan ^a   Xing, Haiyan ^a   Tian, Zheng ^a   Rao, Qing ^a   Wang, Min ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Acute promyelocytic leukemia (APL); Apoptosis; Differentiation; Metformin; Signaling pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; HYBRID PROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; HYPOGLYCEMIC AGENTS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; METFORMIN; ONCOGENE PROTEINS, FUSION; TRETINOIN;

EID: 84861945853     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.001     Document Type: Article

References (30)

1. Witters L.A. The blooming of the French lilac. J. Clin. Invest. 2001, 108:1105-1107.
2. Hundal R.S., Krssak M., Dufour S., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
3. Holland W., Morrison T., Chang Y., et al. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem. Pharmacol. 2004, 67:2081-2091.
4. Zakikhani M., Dowling R., Fantus I.G., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66:10269-10273.
5. Bowker S.L., Majumdar S.R., Veugelers P., et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
6. Libby G., Donnelly L.A., Donnan P.T., et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
7. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2010, 71:3196-3201.
8. Rattan R., Graham R.P., Maguire J.L., et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011, 13:483-491.
9. de The H., Lavau C., Marchio A., et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
10. Kakizuka A., Miller W.H., Umesono K., et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
11. Degos L., Dombret H., Chomienne C., et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85:2643-2653.
12. Fenaux P., Chomienne C., Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 2001, 38:13-25.
13. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
14. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
15. Koken M.H., Puvion-Dutilleul F., Guillemin M.C., et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 1994, 13:1073-1083.
16. Nervi C., Ferrara F.F., Fanelli M., et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 1998, 92:2244-2251.
17. Miranda M.B., McGuire T.F., Johnson D.E. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002, 16:683-692.
18. Green A.S., Chapuis N., Maciel T.T., et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010, 116:4262-4273.
19. Grimaldi C., Chiarini F., Tabellini G., et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2011, 26:91-100.
20. Milella M., Konopleva M., Precupanu C.M., et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 2007, 109:2121-2129.
21. Zhu J., Shi X.G., Chu H.Y., et al. Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia 1995, 9:302-309.
22. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
23. Zhu Q., Zhang J.W., Zhu H.Q., et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002, 99:1014-1022.
24. Lallemand-Breitenbach V., Guillemin M.C., Janin A., et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 1999, 189:1043-1052.
25. Rocha G.Z., Dias M.M., Ropelle E.R., et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 2011, 17:3993-4005.
26. Quenech'Du N., Ruchaud S., Khelef N., et al. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia 1998, 12:1829-1833.
27. Zhao Q., Tao J., Zhu Q., et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 2004, 18:285-292.
28. Yokoyama Y., Kubota M., Iguchi K., et al. Regulation of glyceraldehyde 3-phosphate dehydrogenase expression by metformin in HepG2 cells. Biol. Pharm. Bull. 2009, 32:1160-1165.
29. Glasow A., Prodromou N., Xu K., et al. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005, 105:341-349.
30. Grignani F., Ferrucci P.F., Testa U., et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74:423-431.